Agenus Inc. AGEN
Set alert
At close · Nov 2
After hours · Nov 2, 6:51 PM ET
- YTD
- +107.96%
- 1 year
- +64.48%
- Open
- 6.85
- Prev close
- 6.84
- Mkt cap
- 294.91M
- Vol
- 595.55K
- Avg vol
- 1.08M
- EPS
- 2.53
- P/E
- 2.58
- Div yield
- 0.00%
More statistics
- Low
- 6.43
- High
- 6.86
- Forward P/E
- -0.28
- Beta
- 1.39
- Short ratio
- 4.16
- Inst. own
- 37.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.62
- 200-d avg
- 8.13
- 1y target
- 8.00
News
6 hours ago businesswire.com
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice…
17 hours ago businesswire.com
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the…
1 week ago gurufocus.com
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
[url="]Agenus Inc. (Nasdaq: AGEN)[/url], a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR)
1 week ago businesswire.com
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR)…
1 week ago businesswire.com
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026…
1 week ago marketbeat.com
Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial
Agenus NASDAQ: AGEN is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after…
2 weeks ago defenseworld.net
Agenus Inc. (NASDAQ:AGEN) Stock Has Consensus Price Target of $24.50 According to Analysts
Agenus Inc. (NASDAQ: AGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat reports. One…
3 weeks ago businesswire.com
Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and…
-
3 weeks ago benzinga.com
Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo®…
3 weeks ago businesswire.com
Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has…
3 weeks ago defenseworld.net
ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey
ImageneBio (NASDAQ: IMA - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses…
4 weeks ago defenseworld.net
Agenus (NASDAQ:AGEN) Stock Keeps “Buy” Rating at Chardan Capital
Agenus (NASDAQ: AGEN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Chardan Capital in a research report issued on Monday, Benzinga reports. They…
-
4 weeks ago benzinga.com
Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients
Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of…
1 month ago gurufocus.com
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
1 month ago businesswire.com
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of…
1 month ago gurufocus.com
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
[url="]Agenus Inc.[/url] (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), a
-
1 month ago benzinga.com
Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody,…
1 month ago businesswire.com
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an…
1 month ago benzinga.com
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
-
1 month ago benzinga.com
Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19
Rodman & Renshaw analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $19.
-
1 month ago benzinga.com
Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40
Chardan Capital analyst Andreas Argyrides initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $40.
1 month ago seekingalpha.com
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
1 month ago businesswire.com
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that a poster evaluating botensilimab (BOT), an Fc-enhanced multifunctional…
2 months ago defenseworld.net
Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Here’s Why
Agenus Inc. (NASDAQ: AGEN - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.36 and traded as high as…
2 months ago gurufocus.com
Agenus to Participate in Upcoming September Investor Conferences
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Ar
2 months ago businesswire.com
Agenus to Participate in Upcoming September Investor Conferences
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack…
2 months ago gurufocus.com
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from t
-
2 months ago benzinga.com
Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response
No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response,…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
2 months ago benzinga.com
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25
HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $30 to $25.
-
2 months ago benzinga.com
Agenus Q2 Sales $34.500M Beat $34.000M Estimate
Agenus (NASDAQ:AGEN) reported quarterly sales of $34.500 million which beat the analyst consensus estimate of $34.000 million by 1.47 percent. This is a 34.24 percent increase over sales of $25.700…
-
3 months ago benzinga.com
B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14
B. Riley Securities analyst Mayank Mamtani maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $8 to $14.
3 months ago benzinga.com
Why Is Agenus Stock Falling on Tuesday?
Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.
3 months ago benzinga.com
Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Semiconductor, Twin Vee, JPMorgan In Focus (UPDATED)
U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and S&P 500 indices fell.
3 months ago benzinga.com
Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today
ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose…
3 months ago benzinga.com
Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump
US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech drops 5%. Commodities mixed. European and Asian markets close mixed.
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30
HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $23 to $30.
3 months ago benzinga.com
Why Is Agenus Stock Gaining Monday?
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
3 months ago benzinga.com
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended its cash runway, shelving the Phase 3 BATTMAN trial while doubling down on ROBBIN.
3 months ago benzinga.com
US Stocks Mixed; Dow Gains Over 100 Points
US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on earnings. Oil up 3.9%, gold down 1%.
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…
-
3 months ago benzinga.com
Market-Moving News for July 13th
QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026. AGEN: 36% |…
-
3 months ago benzinga.com
Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in…
-
3 months ago benzinga.com
Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily…
-
4 months ago benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026
Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three-year…
-
5 months ago benzinga.com
Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pretreated Checkpoint-Resistant Melanoma, Including 16.6-Month Median OS and 42% Two-Year Survival
First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease featuresIn the overall BOT+BAL treated…
-
5 months ago benzinga.com
Agenus' Noetik TARIO-2 AI Model Identifies Tumor Microenvironment Signature Predicting 64% Response Rate And Markedly Improved Survival In MSS Metastatic Colorectal Cancer Treated With Botensilimab Plus Balstilimab
Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated patients and identified spatial tumor microenvironment patterns associated with response and survivalIn a…
-
5 months ago benzinga.com
Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilimab In Patients With Treatment-Refractory HCC
Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapyMedian overall survival of 12.3 months in a heavily pretreated population…